Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial-Reference-Cited by-同舟云学术

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

Published:2014-07 Issue:8 Volume:15 Page:799-808
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Monk Bradley J,Poveda Andrés,Vergote Ignace,Raspagliesi Francesco,Fujiwara Keiichi,Bae Duk-Soo,Oaknin Ana,Ray-Coquard Isabelle,Provencher Diane M,Karlan Beth Y,Lhommé Catherine,Richardson Gary,Rincón Dolores Gallardo,Coleman Robert L,Herzog Thomas J,Marth Christian,Brize Arija,Fabbro Michel,Redondo Andrés,Bamias Aristotelis,Tassoudji Marjan,Navale Lynn,Warner Douglas J,Oza Amit M

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Latest research and treatment of advanced-stage epithelial ovarian cancer;Coleman;Nat Rev Clin Oncol,2013

2. Integrated genomic analyses of ovarian carcinoma;Nature,2011

3. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study;Burger;J Clin Oncol,2007

4. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer;Cannistra;J Clin Oncol,2007

5. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?;Kaye;J Clin Oncol,2007

Cited by 267 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

2. Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review;Expert Review of Anticancer Therapy;2024-07-08

3. The efficacy of tyrosine kinase inhibitors combined with chemotherapy for recurrent ovarian cancer: a systematic review and network meta-analysis;Minerva Biotechnology and Biomolecular Research;2024-05

4. Enhanced Theranostic Efficacy of ⁸⁹Zr and ¹⁷⁷Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice;Molecular Pharmaceutics;2024-04-08

5. Effect of angiogenesis inhibitors on wound healing in patients with ovarian cancer: A meta‐analysis;International Wound Journal;2024-03